Enanta reports Q1 EPS ($1.58), consensus ($1.22)

Reports Q1 revenue $18.0M, consensus $22.0M. “In 2024, Enanta began a year which will be marked by execution and value creation across the company. We are preparing for multiple catalysts across our pipeline in 2024, starting with RSV, where we anticipate reporting topline data from the RSVPEDs Phase 2 study of zelicapavir, pending the continuation of a normal Northern Hemisphere RSV season, and the Phase 2a challenge study of EDP-323, in the third quarter of this year,” said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “Beyond RSV, we are excited to leverage our experience in virology and expertise in small molecule drug discovery to develop a robust immunology program, starting with our first program of KIT inhibitors for the treatment of chronic spontaneous urticaria (CSU), a severely debilitating, chronic inflammatory skin disease. We are driven to help the millions of patients impacted by CSU and potentially other mast-cell-driven indications. Furthermore, we plan to expand more broadly into immune-mediated chronic diseases with high unmet need, with the announcement of a second program in 2024. To that end, we will continue to innovate and strengthen our pipeline, sustained by a solid cash position that will support the company well beyond a catalyst-rich 2024.”